Vitiligo-like lesions following imatinib mesylate therapy: a case series and review of literature
Imatinib mesylate (IM), a tyrosine kinase inhibitor, has become a standard of care for the management of chronic myeloid leukemia. The safety profile of IM is favorable; however, few adverse effects such as gastrointestinal disturbances, fluid retention, skin rashes, and myelosuppression have been r...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Series: | Pigment International |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/pigmentinternational.pigmentinternational_52_21 |